Medpace Holdings, Inc.

NASDAQ:MEDP

Medical - Diagnostics & Research

Healthcare
$646.87 -0.98%

-$4.51 today

Market cap
$18.09B
Beta
1.18
P/E (TTM)
28.2
EPS (TTM)
$16.19
52W Low $301.90High $628.92

Volume 0.21M

Average 0.36M

MEDP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Medpace Holdings, Inc.NASDAQ: MEDP

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development remains negative

Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How MEDP compares with its peers on the latest reported figures

  • MEDP's LTM Sep 2026 research & development of $0 is the highest of the 5 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for MEDP, versus a peer median of 0.0%.
MEDP Competitors Peer median
Research & Development for MEDP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MEDPMedpace Holdings, Inc.LTM Sep 2026$0 ——0.0%
IQVIQVIA Holdings Inc.LTM Jun 2026$0 ——0.0%
CRLCharles River Laboratories International, Inc.LTM Jun 2026$0 ——0.0%
ICLRICON Public Limited CompanyLTM Jun 2026$0 ——0.0%
FTREFortrea Holdings Inc.LTM Jun 2026$0 ——0.0%
Peer median (excluding MEDP) $0——0.0%

Competitors are the stored peer set for MEDP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.14B1.46B1.89B2.11B2.53B
Cost of Revenue814.22M1.03B1.36B1.45B1.77B
Gross Profit328.16M432.44M524.51M656.31M760.62M
Gross Margin28.7%29.6%27.8%31.1%30.1%
Research & Development00000
Selling, General & Admin108.42M131.4M161.35M180.18M197.56M
Operating Expenses129.54M153.74M187.68M209.44M225.68M
Depreciation & Amortization21.12M22.34M26.33M29.25M28.12M
EBITDA223.08M308.11M362.5M505.17M570.5M
EBITDA Margin19.5%21.1%19.2%24.0%22.5%
Operating Income198.62M278.7M336.83M446.87M534.94M
Operating Margin17.4%19.1%17.9%21.2%21.1%
Interest Income00025M0
Interest Expense105K2.91M488K00
Other Income / Expenses3.24M4.16M(1.14M)29.05M7.44M
Income Before Tax201.85M282.86M335.68M475.92M542.38M
Pre-Tax Margin17.7%19.4%17.8%22.6%21.4%
Income Tax Expense20M37.49M52.87M71.54M91.25M
Net Income181.85M245.37M282.81M404.39M451.12M
Net Margin15.9%16.8%15.0%19.2%17.8%
EPS (Basic)5.067.579.2013.0615.64
EPS (Diluted)4.817.288.8812.6315.28
Weighted Avg Shares35.86M32.39M30.72M30.96M28.85M
Weighted Avg Shares (Diluted)37.7M33.67M31.84M32.01M29.53M

Medpace Holdings, Inc.

NASDAQ:MEDP

Intrinsic Alpha fair value

Locked

Current Price

$646.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.